Diacon AH, Barry CE 3rd, Carlton A, Chen RY, et al. A first-in-class leucyl-tRNA synthetase inhibitor, ganfeborole, for rifampicin-susceptible tuberculosis: a phase 2a open-label, randomized trial. Nat Med 2024 Feb 16. doi: 10.1038/s41591-024-02829.
PMID: 38365949